首页> 外文期刊>Bone marrow transplantation >Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
【24h】

Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.

机译:匹配的无关骨髓移植治疗慢性粒细胞白血病后14个月,供体细胞衍生的急性髓细胞白血病发展。

获取原文
获取原文并翻译 | 示例
           

摘要

We report a patient with Ph-positive CML who developed a Ph-negative AML in donor cells 14 months after BMT from an HLA-identical male unrelated donor. The Ph translocation could not be detected by either conventional cytogenetics, FISH or RT-PCR analysis excluding relapse of CML in myeloid blast crisis. Chimerism studies were performed by variable number of tandem repeats (VNTR) analysis. These revealed donor-type hematopoiesis in both unseparated mononuclear cells and CD34+ selected blasts proving the leukemia to be of donor origin. The patient received three cycles of polychemotherapy with mitoxantrone, topotecan and ara-c resulting in CR after the first treatment cycle and reconstitution with donor hematopoiesis. A second transplant from a female alternative matched unrelated donor was performed after conditioning with fludarabine and 200 cGy TBI and was well tolerated. Nine months after the second transplant the patient is at home and in CR. T cell chimerism was studied by sex chromosome analysis and revealed complete female donor chimerism.
机译:我们报告了一名来自Ph阳性CML的患者,该患者在来自HLA相同的男性无关供者的BMT后14个月在供体细胞中出现了Ph阴性AML。通过传统的细胞遗传学,FISH或RT-PCR分析都无法检测到Ph的易位,但髓母细胞瘟疫危机中CML的复发除外。通过可变数目的串联重复(VNTR)分析进行嵌合体研究。这些揭示了未分离的单核细胞和CD34 +选择的胚细胞中的供体型造血功能,证明白血病是供体来源的。该患者接受了米托蒽醌,托泊替康和ara-c的三个多化学疗法治疗,在第一个治疗周期后出现CR,并用供体造血重建。在用氟达拉滨和200 cGy TBI进行调理后,进行了第二次移植,该移植来自女性替代性匹配的无关供体,并且耐受性良好。第二次移植后九个月,患者在家中接受CR。通过性染色体分析研究了T细胞嵌合体,并揭示了完全的女性供体嵌合体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号